

SIDC Vision
SIDC’s vision is to become the strength behind an adequately served, healthy, and empowered community by providing the right services and guaranteeing a better quality of life for youth and key affected populations in Lebanon.
SIDC's Mission
SIDC’s mission is to develop social solidarity by reinforcing healthy behaviours in Lebanon through prevention, harm reduction policies, advocacy, and psychosocial services for our target populations (drug users, people living with HIV, vulnerable and stigmatised people).
Our objectives, which go hand-in-hand with the needs of the community and are based on the evaluations and observations executed by our field-working teams, are as follows:
– To inform, prevent, and reduce the number of infections related to HIV, STIs, and risky behaviours, through the awareness of our youth, Drug Users, Female and Male Sex Workers, Men who have Sex with Men, and society on the whole.
– To improve, on the longer run, the living conditions of people made vulnerable by stigma and discrimination in our society by providing them with a surrounding where their dignity and rights are preserved.
– To develop our diverse programmes (HIV and addiction programmes) in order to respond to a community that is increasingly touched by HIV, STIs and addictive behaviours.
– To involve the community actors and policymakers in order to change the laws and prejudices that govern our country.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close